Sleep and Breathing Health's Americas sales supplied 74% of sales growth.
Sleep and Breathing Health's Americas sales supplied 74% of this quarter's net sales growth, a $58.67 M gain out of a $79.23 M total. Residential Care Software fell $11.12 M in the same period, so the total leaned on one region of one business. Even the growth was partly offset by lower life support device sales, which the filing ties to the planned discontinuation of the Astral device. Americas sales of Sleep and Breathing Health rose 8% from a year earlier.
Management's account is about demand: the increase in Americas devices and masks was primarily attributable to increased demand and unit sales. Rest of World grew 8% in constant currency too, which the filing ties partly to device fleet renewals in France. Currency is not the story here, since the filing says movements in international currencies had a negligible impact on Sleep and Breathing Health net revenue. Americas made up 59% of total sales, against 30% for Rest of World.
Put together, the Americas carries the quarter, and its growth rests on demand the filing describes without a single unit count. What it means for a reader is concentration: one region of one business carries most of the growth. Americas sales of $833.42 M are 59% of the company's total, and Rest of World sales of $426.38 M make up 30%. Will the Americas keep carrying the growth, or does its share fall back when the current demand levels off?

